I'm not sure that this has much relevance to IMU at all. Firstly, it doesn't impact the B cell platform and as you have said IMU is not a Car-T company. Secondly the oncolytic virus delivery is not the same as that used in the study i.e. Vaccinia vs Lentivirus and YF has explicitly said it doesn't go near the DNA of the patient, only cancer cells. Finally, chromosomal abnormalities can occur for lots of reasons so while the trial is on hold, it doesn't mean the method employed is the cause. What it might mean for Celularity is that they are better off working with IMU.
I'm not sure that this has much relevance to IMU at all....
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
-0.005(6.10%) |
Mkt cap ! $563.6M | |||
| Open | High | Low | Value | Volume |
| 8.2¢ | 8.3¢ | 7.6¢ | $1.931M | 24.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 1392733 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 140950 | 2 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
-0.005 ( 6.71 %) |
||||
| Open | High | Low | Volume | ||
| 8.2¢ | 8.3¢ | 7.6¢ | 9515046 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| IMU (ASX) Chart |